NEELY MOZAFFARIAN, M.D., PH.D.
AUTOANTIBODY PATHWAY AREA LEADER
Neely Mozaffarian, M.D., Ph.D., is Vice President, Autoantibody Pathway Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Neely is responsible for the design and implementation of the scientific strategy for the Autoantibody Pathway portfolio, partnering with teams across the Janssen therapeutic area to identify external opportunities and platforms required for next-generation approaches to the autoantibody pathway targets.
Prior to her role at Janssen, Neely led a team in global clinical drug development for small and large molecules and was responsible for strategy and deliverables for autoimmunity and rheumatology programs as Senior Vice President at Ichnos Sciences, a subsidiary of Glenmark Sciences.
Prior to joining Ichnos, Neely served as Group Leader, Global Autoimmunity and Rheumatology Clinical Research and as Executive Director, Clinical Research, Inflammation and Respiratory Therapeutics at Gilead Sciences. Before joining Gilead, she held positions focusing on rheumatology and immunology at Lilly, AbbVie and Bristol Myers Squibb.
Neely earned her M.D. and Ph.D. degrees from Albert Einstein College of Medicine in New York. She trained in internal medicine and rheumatology at the University of Washington, Seattle and has authored numerous abstracts and scientific articles.
Follow Neely on LinkedIn here.